China Women’s Health Market Size & Outlook, 2023-2030
China women’s health market, 2018-2030 (US$M)
Related Markets
China women’s health market highlights
- The China women’s health market generated a revenue of USD 2,180.8 million in 2023 and is expected to reach USD 3,966.1 million by 2030.
- The China market is expected to grow at a CAGR of 8.9% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 2,180.8 million |
| Market revenue in 2030 | USD 3,966.1 million |
| Growth rate | 8.9% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, China accounted for 4.9% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan women’s health market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 3,966.1 million by 2030.
Contraceptives was the largest segment with a revenue share of 35.84% in 2023. Horizon Databook has segmented the China women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
According to a survey on women's health in China, over 21.5% of women suffered from chronic diseases, and the prevalence of gynecological diseases was estimated at more than 13%. Furthermore, according to the National Reproductive Health Survey 2020, the infertility rate in China has substantially increased; in 2007, it was 12%, which increased to 18% in 2020.
One out of 5.5 couples faces infertility issues in China. Such factors are likely to increase the demand for hormonal infertility products in China over the forecast period. Moreover, chronic disorders and women's health issues related to pre- & postmenopausal complications may increase the demand for women's health products in this country.
For instance, according to a recent study in China, around 15% of women of reproductive age suffer from endometriosis. Moreover, increasing collaborations between research institutes and pharmaceutical companies to introduce novel pharmaceutical drugs are expected to drive market growth in the country.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China women’s health market size, by application, 2018-2030 (US$M)
China Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
